Skip to content

Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples

Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04298255
Acronym
ROSI
Enrollment
50
Registered
2020-03-06
Start date
2020-08-24
Completion date
2028-07-01
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Male

Keywords

IVF, Fertility

Brief summary

The purpose of this research study is to evaluate if special types of cells called round spermatids can be gathered from men with non-obstructive azoospermia and used (in absence of elongated spermatids and spermatozoa) to reliably and effectively create pregnancy with a procedure called Round Spermatid Injection (ROSI). This process is similar to In Vitro Fertilization, or 'IVF'. In addition, this study wants to test the safety of ROSI and see what effects (good and bad) it has on embryo created from this method.

Detailed description

Azoospermia is defined as the absence of sperm in the ejaculate. Around 1% of general population suffers from azoospermia. Men who were rendered infertile due to a non-obstructive azoospermia, who have been subjected to Testicular Sperm Extraction (TESE) surgery and found to be lacking elongated spermatids or spermatozoa, are commonly advised to consider utilizing a sperm donor or apply for adoption. It is reported that \ 30% of men with non-obstructive azoospermia lack elongated spermatids and spermatozoa but may still produce round spermatids (less mature form of haploid germ cells) in their testicles. Round Spermatid Injection (ROSI) technology to fertilize oocytes is not a brand-new technology, however, it is plagued with notoriously low efficiency. Despite this limitation, it has been reported that most of these patients still desire to have the ROSI procedure instead of applying directly for other options, i.e. sperm donation or adoption. High failure rate of traditional ROSI has been attributed to a few potential causes: 1. Incorrect selection of round spermatids (to distinguish from diploid spermatogonia cells) 2. Using round spermatids that were already in the process of degeneration 3. Incomplete imprinting in the round spermatid 4. Incomplete activation of oocytes Recently Tanaka and colleagues in Japan established a new ROSI method and reported over 90 babies born via this method1. They described a new method of round spermatid selection and oocyte activation using NEPA21 super electroporator (10 minutes prior to round spermatid injection). Babies born from this new ROSI method in Japan have been evaluated for developmental and cognitive differences for 2 years1. Babies conceived with ROSI were found to have a shorter gestation times, and lower body weight at 12 and 18 months when compared to their naturally conceived counterparts, but also showed an increased birth weight and showed no body weight differences at 24 months of age. No diseases resulting from genetic anomalies have been reported thus far, but the relatively small sample sizes present in the literature needs to be tested in larger cohorts. Therefore, this effective ROSI method should still be considered as an "experimental fertility treatment".

Interventions

OTHERRound Spermatid Injection (ROSI)

In Vitro Fertilization using Round Spermatid Injection (ROSI)

OTHERHalf ROSI-half Sperm Donor Fertilization

Half ROSI-half Sperm Donor Fertilization

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER
Carolinas Fertility Institute (CFI)
CollaboratorUNKNOWN
Wake Forest Institute for Regenerative Medicine (WFIRM)
CollaboratorUNKNOWN
Wake Forest Department of Urology
CollaboratorUNKNOWN

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Infertile Male with round spermatid (but not elongated spermatids and spermatozoa) in their testes. Couples can choose either option 1 or 2.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males with no elongated spermatids or spermatozoa present but with round spermatids present on TESE (Testicular Sperm Extraction) * Male diagnosed with non-obstructive Azoospermia * Male partner ≥18 * Female partner greater than 18 years of age and less than 38 years of age or Anti Mullerian Hormone (AMH) greater than 2 ng/ml.

Exclusion criteria

* Males with obstructive azoospermia * Males with presence an adequate number of elongated spermatids or spermatozoa

Design outcomes

Primary

MeasureTime frameDescription
Fertility rateDay 1 after round spermatid injectionEgg fertilization comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms.This fertilization process will be recorded by EmbryoScope under supervision of dedicated clinical embryologist.All the process will be followed and documented according to America Society of Reproductive Medicine (ASRM) guidelines. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.

Secondary

MeasureTime frameDescription
Blastocyst formationDay 3 to 5 after round spermatid injectionBlastocyst comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms.Embryo grow and blastocyst formation will be recorded by EmbryoScope under supervision of dedicated clinical embryologist.All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Aneuploidy rateDay 3 to 5 after round spermatid injectionAneuploidy comparison and evaluation of abnormality between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Aneuploidy will be tested using polymerase chain reaction amplification (PCR) based Preimplantation genetic diagnosis (PGD) and fluorescent in situ hybridization (FISH) analyses. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Chemical Pregnancy with Positive human chorionic gonadotropin (hCG)Post Fertilization 4 Weeks and onwardsPregnancy Rate between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Blood test to measure beta-hCG (chemical pregnancy) and follows by Ultrasound (clinical pregnancy). All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Live Birth RatePost Pregnancy Full Term Average 39 to 40 weeksLive Birth comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Pregnancy will be followed as high risk and health of born children will be evaluated by a dedicated neonatologist/Pediatrician. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.

Countries

United States

Contacts

CONTACTKarla M Oliver
kaoliver@wakehealth.edu336-713-3123
PRINCIPAL_INVESTIGATORHooman Sadri, MD, PhD

Wake Forest Institute for Regenerative Medicine (WFIRM)

STUDY_DIRECTORHooman Sadri, MD, PhD

Wake Forest University Health Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026